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Pancreatic cancer is a malignancy of poor prognosis which is mostly diagnosed at advanced stages. Current treatment modalities
are very limited creating great interest for novel preventive and therapeutic options. Vitamin D seems to have a protective eﬀect
against pancreatic cancer by participating in numerous proapoptotic, antiangiogenic, anti-inﬂammatory, prodiﬀerentiating, and
immunomodulating mechanisms. 25-hydroxyvitamin D [25(OH)D] serum concentrations are currently the best indicator of
vitamin D status. There are three main sources of vitamin D: sun exposure, diet,and dietary supplements. Sun exposure has
been associated with lower incidence of pancreatic cancer in ecological studies. Increased vitamin D levels seem to protect against
pancreatic cancer, but caution is needed as excessive dietary intake may have opposite results. Future studies will verify the role of
vitamin D in the prevention and therapy of pancreatic cancer and will lead to guidelines on adequate sun exposure and vitamin D
dietary intake.
1.Introduction
1.1. Epidemiology. Pancreatic cancer exhibits some of the
lowest overall survival rates in oncology, and its incidence
has been underestimated for years. Approximately 6% of all
cancer-related deaths are associated with pancreatic cancer
and around 32,000 Americans are diagnosed and die from
this disease annually [1]. It is the fourth leading cause
of cancer mortality in both men and women. One-year
and 5-year survival rates are estimated at 24% and 4.3%,
respectively [2]. One of the main reasons for this dismal
prognosis is the lack of an eﬀective screening method as
pancreatic cancer is diﬃcult to diagnose in its early disease
stages. At time of diagnosis, 52% of patients have distant
metastases and in 26% of cases, the disease has spread locor-
egionally [2].
Pancreatic cancer has a higher prevalence among men
and African-Americans. Results from several epidemiologic
studies have suggested that several environmental factors
may be associated with developing pancreatic cancer, but
tobacco smoking was the only established risk factor [3].
It was shown that a larger waist circumference and waist-
to-hip ratio were associated with a statistically signiﬁcant
increased risk of developing pancreatic cancer, although
greater body mass index and lack of total physical activity
were not identiﬁed as risk factors [3]. According to Patel et
al., obesity and central adiposity are correlated to increased
pancreatic cancer risk [4]. Diabetes mellitus was associated
with greater pancreatic cancer incidence [5, 6], although
there is limited data supporting the theory that sugars or
sweets are pathogenetically implicated [7]. Finally, high red
and processedmeat intakewas linkedtoelevatedriskbutthis
isprobablysecondarytocarcinogenicsubstancesusedduring
meat processing.
1.2. Current Treatment Modalities. The only existing pan-
creatic cancer treatment which oﬀers the potential of cure
is surgical resection. Nevertheless, as stated above, most2 Journal of Nutrition and Metabolism
patients are diagnosed at advanced stage and are not likely
candidates for surgical therapy [2].
Despite continuing research, limited progress has been
made in the treatment of advanced pancreatic cancer. For
overa decade,gemcitabinewas theacceptablestandard treat-
ment,butits useas monotherapy in advanced and metastatic
stages of pancreatic cancer has been in question as only
small beneﬁt has been shown. Multiple gemcitabine-based
therapeutical regimens have been studied (i.e. gemcitabine
combined with molecular targeting agents, farnesyltransfer-
ase inhibitors, and metalloproteinase inhibitors) [2]. The
combination of gemcitabine plus erlotinib is the only one
that seems to prolong survival [8].
Therefore, treatment for patients with advanced pancre-
atic cancer is primarily palliative. Initial monotherapy with
5-ﬂuorouracil (5-FU) has been widely administered, but it
did not demonstrate any beneﬁt for overall quality of life
or survival. Response rates were less than 10% [9]. Clinical
trials with chemoradiation and multiple chemotherapeutic
regimens (doxorubicinordoxorubicin/mitomycin,cisplatin)
alongside 5-FU failed to prolong overall survival, although
response rates were better with some of the regimens.
Increased toxicity was another reason that these regimens
were not explored further [10–12].
1.3. Genetic Basis for Pancreatic Cancer. The genetic basis of
pancreatic cancer has been extensively studied. Mutation or
silencing of p53, p1, and DPC4/s mad4 genes is associated
with pancreatic cancer, but K-ras mutations (in codons 12,
13, and 16) are the most frequently noticed mutations [13].
K-ras mutations have also been found to poor prognos-
tic factors for patients who have undergone surgery and
adjuvant chemoradiation. It should also be noted that in a
preclinical study Fleming et al showed that certain deleting
K-ras mutations may result in altering cancerous behavior of
pancreatic tumor cells [14].
2. Vitamin D Is a ProtectiveFactor
Due to the fact that pancreatic cancer carries one of highest
mortality rates and is very resistant to treatment, there
are eﬀorts to ﬁnd protective factors. Vitamin D seems to
prevent not only pancreatic cancer, but also colon, ovary,
and breast cancer [15–18]. According to a most recent
epidemiological analysis by Garland et al, raising serum
levels of vitamin D would prevent 58000 new cases of breast
cancer and 49000 of new cases of colorectal cancer each year
[19].
2.1. Sources of Vitamin D. There are three main vita-
min D sources for humans: sunlight exposure (ultraviolet
B radiation: UVB), diet, and dietary supplements [20, 21].
Sunlight irradation is the most important, and early-life
exposure has already been associated with decreased cancer
risk in several malignancies, such as prostate cancer [22–
24]. Brief body exposure directly to direct sunlight during
summer is all that isrequired to make enough cholecalciferol
(vitamin D3) for the daily vitamin D requirements. During
sun exposure, UVB radiation (wavelength of 290 to 315nm)
pierces through the skin and converts 7-dehydrocholesterol
(provitamin D3) in the skin to previtamin D3. Since previta-
min D3 is very unstable, it is rapidly transformed to its more
stable form of vitamin D3, which is then absorbed across
the subcutaneous capillary bed to enter general circulation
[20, 25]. Mohr et al. (2010) conﬁrmed earlier ﬁndings that
the incidence of pancreatic cancer was higher in countries
with lower UVB irraidiance [26]. There is an ever growing
number of ecological studies regarding cancer incidence that
corroborate the inverse correlation of pancreatic cancer to
solar UVB exposure in Western and in Asian countries [27–
34]. Ecological studies are very helpful when examining such
a topic, as much of the risk for cancer occurs with early-life
eﬀects in the ﬁrst 20 years of life, starting with conception
[35]. A recent study used Hill’s criteria of causality to assess
the value of UVB and vitamin D in reducing cancer risk and
concludedthatresultsfor severalcancerssatisfy these criteria
[36, 37]. Vitamin D intoxication secondary to prolonged
sun exposure is not observed, as excess previtamin D3 and
vitamin D3 readily absorb sunlight and are converted into
inactive photoproducts [38]. Thus, vitamin D intoxication
through sunlight has never been reported in life guards,
who experience excessive sun exposure [38]. There are
public health concerns since excess ultraviolet radiation
exposure is implicated in skin cancer, development of
cataract, premature photoageing and skin hypersensitivity
when certaindrugsareconcomitantlyused,evenwithashort
amount of time of sun exposure [39]. It is worth noting
that vitamin D produced which during the sunny months
(spring, summer and fall) is stored in the body fat but it is
not known whether it can be actually used in winter months,
unless, maybe, in case of signiﬁcant adipose tissue loss
[40]. Unfortunately, vitamin D production through sunlight
exposure is often not suﬃcient for people with dark skin,
urban areas as well as for those largely conﬁned indoors
[39, 41, 42]. Furthermore, latitude plays an important role
because in temperate zones (23.5◦–66.5◦), people are unable
to synthesize vitamin D for 1 month of the year due to
insuﬃcient UVB and those nearer to the poles (>66.5◦)
do not get enough UVB radiation for most of the year
[43, 44].
In absence of required sunlight exposure, vitamin D
can be obtained from dietary sources or supplements [39].
Only few foods are known to naturally contain considerable
amounts of vitamin D: oily ﬁsh such as sardines, salmon,
and mackerel and ﬁsh oils such as cod liver oil [40, 45].
Certain foods, such as milk, orange juice, bread, and cereal,
are fortiﬁed with vitamin D [46–48]. There are two forms
of supplemental vitamin D, D2, and D3 [45]. Ergosterol is
produced in plants and yeast, whereas 7-dehydrocholesterol,
which is its immediate precursor in the cholesterol biosyn-
thetic pathway, is produced in animals [40, 45]. UVB sun-
light radiation converts ergosterol and 7-dehydrocholesterol,
into vitamin D2 (ergocalciferol) and D3 (cholecalciferol),
respectively [40, 45]. Although some believe D3 is more
potent than D2 [49], this has not been conﬁrmed by the
literature [50].Journal of Nutrition and Metabolism 3
2.2. Metabolism of Vitamin D. Vitamin D (both D2 and D3
forms) isconverted to 25-hydroxycholecalciferol [25(OH)D-
also known ascalcidiol]in the liver. This formis thenfurther
hydroxylatedto1,25-dihydroxycholecalciferol[1,25(OH)2D-
also known as calcitriol] in the kidneys [20, 21]. 25-
hydroxycholecalciferol is used to measure the vitamin D
levels, although 1,25-dihydroxycholecalciferol is the active
form [20, 21]. Therefore, hereon in this review, the term
vitamin D will refer to 25-hydroxycholecalciferol, unless
otherwise stated. High-aﬃnity receptors in the nucleus help
the active compound regulate gene transcription in many
cells [21]. They are found not only in target organs (gut,
bone, kidney, and parathyroid) [51], but also in many other
tissues, such as brain, breast, colon,heart, pancreas, prostate,
skin, and the immune system [52]. The rate-limiting step
of the vitamin D conversion pathway is interesting: the
vitamin D 1-α-hydroxylase enzyme converts 25(OH)D to
1,25(OH)2Dandwasinitiallythoughttoexistonlyinkidneys
which regulate the systemic levels of vitamin D. It has been
recently found that this enzyme is expressed in many other
organs as well, such as the pancreas. This locally produced
calcitriol does not enter systemic circulation and therefore
does not aﬀect calcium metabolism. It remains in the region
and oﬀers protection to the cells that produce it and cells
nearby [52].
2.3. Protective Action of Vitamin D and Probable Molecular
Mechanisms. TheimportanceofvitaminDincancerpreven-
tion was originally derived from epidemiological data that
associated season of diagnosis and sun exposure with cancer
incidence and mortality [53–62]. From these observational
studies, it was obvious that sun exposure was inversely
correlated to cancer incidence and mortality. Protective
features of solar radiation exposure have been attributed to
elevated serum levels of 25(OH)D.
This hypothesis was later supported by dietary [58, 63]
andmechanistic studies[64–66].Ithasbeenshown thatvita-
min D not only has a protective but also a therapeutic eﬀect
on many malignancies [67–72]. These actions of vitamin D
are mediated by a number of proapoptotic, antiangiogenic,
anti-inﬂammatory, prodiﬀerentiating, and immunomodu-
lating mechanisms [16, 73, 74]. Despite theoretical concerns,
evidence-based studies have shown that vitamin D has no
adverse eﬀect on chemotherapy or radiation therapy [75].
More over, there seems to be synergy with chemotherapy
and radiotherapy. The role of vitamin D as an anticancer
agent is just starting to be explored; however, initial results
are promising [76–78]. A recent phase II study showed
that high-dose calcitriol with docetaxel may increase time
to progression in patients with incurable pancreatic cancer
when compared to docetaxel monotherapy [79]. Paricalcitol
is a less calcemic vitamin D analogue which has been found
tobein vitroand in vivoeﬀectiveininhibiting tumorgrowth
in vitro and in vivo, via upregulation of p21 and p27 tumor
suppressor genes. It constitutes an attractive novel therapy
for pancreatic cancer [74].
The active form of vitamin D, 1,25(OH)2D, or calcitriol
is as a steroid hormone involved in molecular mechanisms
that prevent cellular malignant transformation. Some of
the vital cellular actions of vitamin D are involved in
intracellular signaling pathways [66], cell cycle and cellular
growth [80, 81], diﬀerentiation [82, 83], adhesion [84], and
apoptosis [85, 86]. Calcitriol mediates all these actions by
binding to a nuclear receptor known as vitamin D receptor
(VDR), which is expressed in many cell types [87]. It
enters the cellular cytoplasm and binds to nuclear VDR.
This complex migrates to the nucleus, binds to vitamin
D-responsive elements (VDREs), and activates promoters
of responsive target genes. Based on the type of complex
formed, calcitriol regulates initiation or suppression of gene
expression [84]. A brief account of the eﬀects of vitamin D
on cell division, diﬀerentiation, adhesion, and apoptosis is
summarized below.
(1) Cellular division and diﬀerentiation.
(i) Vitamin D regulates the levels of p21 and p27,
which in turn control the cell cycle [88].
(ii) Cyclin D activates cyclin-dependant kinases
(CDKs) in order to increase transcription of
genes controlling the transition from G1 to S
phase. Calcitriol binds to cyclin D and inhibits
this transition [88].
(iii) The accuracy of DNA replication and DNA
repair is controlled by cell cycle surveillance
mechanisms. Tumor suppressor gene p53 is
activated in case of DNA damage and increases
p21 levels; therefore, CDKs are inhibited and
cell cycle arrest is induced. Vitamin D is in-
volvedinthisprocessasitregulatesp21andp53
levels [89, 90].
(iv) Calcitriol increases expression of BRCA-1 and
-2 tumor suppressor genes contributing in the
DNA repair mechanism [91].
(2) Cell adhesion: when a cancer cell loses its adhesion
features, it acquires metastatic potential. Calcitriol
increases E-cadherin and changes the location of β-
catenin, reducing intracellular mRNA concentration
of c-myc [69].
(3) Cell death (apoptosis): caspases mediate apoptosis
and are activated by p53, which is increased in DNA
damage. Calcitriol upregulates genes involved in
apoptosis by regulating p53 levels [92, 93].
Vitamin D is implicated in other molecular pathways as
well. It is known to decrease vascular growth factor (VEGF),
which is essential in tumor angiogenesis [45]. VDR growth
controlhasbeenrecentlyfoundtovary considerablybetween
diﬀerent malignancies suggesting tissue-speciﬁcity of the
above vitamin D dependent pathways [94]. Finally, vitamin-
D-binding-protein (DBP) is considered to be deglycosylated
in cancer patients causing inability to activate macrophages.
More speciﬁcally, Gc protein-derived macrophage activating
factor (GcMAF) is a naturally derived form of human DBP
with a single terminal O-linked GalNac sugar residue and
plasma levels of O-linked trisaccharide glycosylated DBP4 Journal of Nutrition and Metabolism
have been found associated with GcMAF precursor activity.
Studies in cancer patients have shown that α-N-acetylgalac-
tosaminidase (nagalase) activity is inversely correlated to this
precursoractivity, and this couldexplain why cancerpatients
are relatively unable to activate macrophages. However,
r e p o r t so nt h i ss u b j e c th a v eb e e nc o n ﬂ i c t i n g[ 95].
Recent studies have demonstrated the role of vitamin D
in pancreatic cancer. It reduces the risk for pancreatic cancer
by regulating cell cycle and diﬀerentiation [96]. Vitamin D
1-α-hydroxylase enzyme levelswere found elevated in malig-
nantpancreaticcells,suggestingthatvitaminDisaprotective
factor [96]. EB1089, an calcitriol analogue with low calcemic
activity, is a potent inhibitor of parathyroid hormone-related
peptide (PTHRP) production in vitro and has shown protec-
tive features concerning proliferation and diﬀerentiation of
pancreatic cancer cells [97] and xenografted malignant cells
[98].
2.4. Role of Dietary Vitamin D. Although several environ-
mental factors have been studied, only smoking has been
found to be strongly associated with pancreatic cancer.
Serum levels of vitamin D have been extensively studied in
several malignancies. Prediagnostic levels were not always
associated with incidence [99] but numerous studies have
shown that higher serum levels at diagnosis are correlated
with increased survival [100–104]. The literature concerning
the role of diet in the development of pancreatic cancer is
minimal. One study that examined dietary vitamin D intake
and pancreatic cancer was not able to show an association
[105]. However, this could be attributed to the fact that the
median reported dietary intake of vitamin D in this study
was about half of the U.S. deﬁned required daily intake
of vitamin D. Skinner et al. suggested a role of dietary
vitamin D in pancreatic cancer oncogenesis and prevention.
They monitored dietary vitamin D intake and pancreatic
cancer incidence over a period of 16 years. They used
a standardized 131-item semiquantitative food-frequency
questionnairetomonitorvitamin Dintake.The ﬁnalanalysis
of their prospective cohort study showed that participants
that consumed ≥600IU/d of dietary vitamin D had 41%
lower risk for pancreatic cancer when compared to those
consuming <150IU/d [63]. The results of the American
Institute for Cancer Research Report [106]a sw e l la st h o s eo f
themostrecentsystematic reviewoftheTuftsPracticeCenter
sponsored by the Institute of Medicine and the World Health
Organization [107] have been valuable regarding vitamin
D-calcium interactions and Dietary Reference Intake (DRI)
recommended values are concerned. Nonhypercalcemic
analogues of the active form of cholecalciferol may oﬀer
chemoprevention against gastrointestinal cancer by tightly
regulating cell diﬀerentiation.
One of the major limitations in the analyses of these
studies is the lack of an accurate nutrient database in order
to assess vitamin D levels in dietary, supplemental and
pharmaceutical sources. A widely accepted reference is the
United States Department of Agriculture (USDA) National
NutrientDatabase,which iscurrentlybeingrevised. The new
version should be compared to the current one in order to
assess, whether theassociation which foundbetween vitamin
D and pancreatic cancer actually exists.
2.5. Adequate Levels and Sources of Vitamin D. There is
a continuous debate concerning the adequate level of
vitamin D in the human body. Even though there is no
established consensus, 25(OH)D levels lower than 20ng per
liter (50nmol per liter) are usually deﬁned as vitamin D
deﬁciency [108, 109]. 25(OH)D levels ranging from 21–
29ng (52–72nmol per liter) are considered as relatively
insuﬃcient and levels greater than 30ng (75nmol per
liter) can be accepted suﬃcient [110, 111]. Finally, experts
consider levels exceeding 150ng per liter (374nmol per
liter) as vitamin D intoxication [45]. Unfortunately, all these
reference levels are based on myoskeletal studies and the
required levels for nonskeletal functions might be diﬀerent.
In malignancies, vitamin D levels are high both systemically
as well as locally therefore, the optimum level is expected
to be higher. Garland et al. assume that this level will be
at least as high as 40 to 50ng/mL (100–125nmol/L), and
some experts consider these levels as adequate to prevent
malignancies [16, 73]. However, opinions vary as cohorts
have contradictory results on this subject [112, 113]. A
most recent study reported that greatly increased vitamin D
concentrations were associated with a statistically signiﬁcant
2-fold increase in overall pancreatic cancer risk therefore,
recommendations on increasing vitamin D intake should be
thoroughly considered [114].
Regarding the distribution of pancreatic cancer risk,
there have been two studies suggesting a U-shaped serum
25(OH)D level dose-disease relation [115, 116]. These
ﬁndings have not been reproduced by other studies but the
diﬀerences may be attributed to diﬀerences in the vitamin
D pancreatic risk association between men and women [63],
smokers andnonsmokers [117],and high andlowresidential
UVB exposure [115]. A critical approach by Grant et al.
(2009)[117]supportsthatdataonU-shaped distributionare
too limited to be used as basis for public health policies. The
review of the International Agency for Research on Cancer
also noted the need to further assess the potential for U-
shaped association between vitamin D status and risk of
pancreatic cancer [116].
I no r d e rt oa c h i e v es e r u ml e v e l so f5 0 n g / m l ,o r a ls u p -
plementation of 4000IU/day vitamin D is recommended or
a supplementation of 2000IU/day plus 12 minutes of daily
sun exposure of 50% of the body surface area [16]. These
doses are very unlikely to cause intoxication; however, it
is advisable to monitor vitamin D levels every 3 months.
Finally, optimum and adequate levels of vitamin D need to
be deﬁned for each disease category and recommendations
are still under debate. Even though the daily dietary require-
mentsvarywithageandsunexposure,thecurrentlyaccepted
vitamin D daily dietary intake is 200–600IU/day [16].
2.6. Assessment of Vitamin D Levels. Serum 25(OH)D is
used to estimate vitamin D body levels. However, as most
tissues express vitamin D 1-α-hydroxylase (CYP27B1), the
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increased locally. Therefore, based on the systemic levels of
25(OH)D,wearelikelytounderestimatethelocalactiveform
concentration, which is the most important factor for tumor
suppression [16]. Depending on sun exposure, 25(OH)D
levels also tend to ﬂuctuate around the year. Daily levels do
not ﬂuctuate signiﬁcantly within the same season, but they
are known to vary greatly between seasons. Consequently, it
should be noted that serum levels reﬂect dietary intake as
well as sun exposure and they do not represent long-term
exposure, which is of interest in epidemiological studies.
Serum vitamin D levels are also thought to be inﬂuenced
by genotype (VDR polymorphisms, CYP27A1, CYP27B1,
CYP24A1 variant alleles) as the latter aﬀects vitamin D
transport and metabolism [73, 118–120]. The best method
of estimating vitamin D serum levels is yet to be deﬁned.
3.Conclusion
Recent literature has provided plenty of information con-
cerning the preventive and therapeutic role of vitamin D
in many malignancies, including pancreatic cancer. Daily
doses needed to achieve protective levels have not been
determined yet, and it is possible that levels vary between
cancer types and stages. Increase vitamin D levels seem to
protect against pancreatic cancer but caution is needed as
greatly increased dietary intake may have opposite results.
No accurate nutrient database has been established yet;
therefore,interpretationofdatashouldbedonewithcaution.
Better assessment of sun exposure in the future as well as
better food compositional data may help clarify whether
the association between vitamin D and pancreatic cancer
actually exists. Ongoing clinical trials will assist in verifying
the role of vitamin D in the prevention and therapy of
pancreatic cancer and in clarifying the molecular pathways
implicated. Future studies will lead to guidelines concerning
adequate sun exposure and vitamin D dietary intake.
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